- Home
- GRFS vs JAZZ Comparison
GRFS vs JAZZ Comparison
Compare GRFS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- JAZZ
- Stock Information
- Founded
- GRFS 1940
- JAZZ 2003
- Country
- GRFS Spain
- JAZZ Ireland
- Employees
- GRFS 23737
- JAZZ N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- GRFS Health Care
- JAZZ Health Care
- Exchange
- GRFS Nasdaq
- JAZZ Nasdaq
- Market Cap
- GRFS 5.5B
- JAZZ 6.5B
- IPO Year
- GRFS 2006
- JAZZ 2007
- Fundamental
- Price
- GRFS $8.05
- JAZZ $122.49
- Analyst Decision
- GRFS Sell
- JAZZ Buy
- Analyst Count
- GRFS 2
- JAZZ 14
- Target Price
- GRFS $10.50
- JAZZ $173.93
- AVG Volume (30 Days)
- GRFS 1.3M
- JAZZ 539.6K
- Earning Date
- GRFS 01-01-0001
- JAZZ 11-06-2024
- Dividend Yield
- GRFS N/A
- JAZZ N/A
- EPS Growth
- GRFS N/A
- JAZZ 458.10
- EPS
- GRFS 0.27
- JAZZ 7.04
- Revenue
- GRFS $7,814,096,584.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- GRFS $8.86
- JAZZ $7.51
- Revenue Next Year
- GRFS $7.00
- JAZZ $6.82
- P/E Ratio
- GRFS $35.12
- JAZZ $17.38
- Revenue Growth
- GRFS 7.21
- JAZZ 5.23
- 52 Week Low
- GRFS $5.30
- JAZZ $99.06
- 52 Week High
- GRFS $12.15
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- GRFS 51.40
- JAZZ 53.16
- Support Level
- GRFS $7.29
- JAZZ $121.22
- Resistance Level
- GRFS $7.85
- JAZZ $126.23
- Average True Range (ATR)
- GRFS 0.33
- JAZZ 2.83
- MACD
- GRFS 0.06
- JAZZ -0.23
- Stochastic Oscillator
- GRFS 77.22
- JAZZ 50.43
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.